A subset of patients tested for EGFR mutations were evaluated with NGS tests that include other cancer mutation hotspots, enabling assessment of other oncogenes from the EGFR pathway that are frequently mutated in lung cancer. The gene discussed is EGFR; the disease is lung carcinoma.